Satyadeva Pharmaceuticals Private Limited - Due diligence report

A 360° intelligence report on Satyadeva Pharmaceuticals Private Limited: trust score, financial health, credit view, compliance, directors, …

2000-08-11 Medak, Telangana Active Unlisted Active Compliant
Share
Connect MCP
SP Satyadeva Pharmaceuticals Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Satyadeva Pharmaceuticals Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
92/100
Trust Score
Low Risk

Satyadeva Pharmaceuticals Private Limited is assessed as Low Risk with a Trust Score of 92/100. Satyadeva Pharmaceuticals Private Limited is an active private limited indian non-government company incorporated in 2000, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 13 Aug 2026 from the latest processed filings. Satyadeva Pharmaceuticals Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
92/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
85/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
90/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
55/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 90/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • Moderate gearing (D/E 1.42).
  • Profitable - internal accruals available.

Charges position: 3 open (13.09 cr) · 5 satisfied (39.65 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Axis Bank Limited2 48.0 cr
Hdfc Bank Limited2 48.0 cr
Others1 48.0 cr
State Bank Of India (Balkampet Branch)1 48.0 cr
Andhra Bank2 48.0 cr
Compliance Score: 100/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
SWATHI NANDAMURI 01234567 Director 01/04/2018 6 yrs Approved
ESWARA NARAYANA KOSARAJU 01234567 Director 01/04/2018 6 yrs Approved
SRINIVASA RAO TUBATI 01234567 Director 01/04/2018 6 yrs Approved
VENKATA PRASAD AVERINENI 01234567 Director 01/04/2018 6 yrs Approved
HARI KRISHNA KOSARAJU 01234567 Director 01/04/2018 6 yrs Approved
  • 5 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2025 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
0 allotment(s) · 5 transfer(s)

Key managerial personnel: ESWARA NARAYANA KOSARAJU (Managing Director) · SRINIVASA RAO TUBATI (Whole-time director) · VENKATA PRASAD AVERINENI (Whole-time director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 55 · Distress 80
Growth signals & trust indicators
Profit expanded 2.1x year-on-year.
Net margin improved to 24%.
Operating for 26+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 0.86 in a year.
3 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence92/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment91/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 3 open charge(s) of 13.09 cr already registered.
  • Compliance record supports lending.
Investor view75/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
13 Mar 2025
Charge created
Hdfc Bank Limited - 99.00 Lakh
07 Nov 2024
Charge created
Others - 5.00 cr
31 Mar 2021
Share transfer (FY 2021)
20000.00000000 shares to Sudha Rani Yarra
31 Dec 2020
Director ceased
SRINIVASA RAO TUBATI
Director ceased
VENKATA PRASAD AVERINENI
11 Sep 2020
Charge satisfied
Hdfc Bank Limited
03 Jan 2020
Charge satisfied
Axis Bank Limited
01 Apr 2019
Director appointed
SWATHI NANDAMURI (Director)
Director appointed
HARI KRISHNA KOSARAJU (Director)
31 Mar 2019
Share transfer (FY 2019)
300000.00000000 shares to Hari Krishna Kosaraju
Share transfer (FY 2019)
60000.00000000 shares to Hari Krishna Kosaraju
Share transfer (FY 2019)
185000.00000000 shares to Swathi Nandamuri
30 Oct 2017
Charge created
Hdfc Bank Limited - 18.00 cr
10

Key Observations

Auto-generated from the data above
Revenue declined 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
5 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Indian Emulsifiers Limited L46691MH2020PLC351364 Mumbai, Maharashtra, India
Kronox Lab Sciences Limited L24117GJ2008PLC055460 Padra, Gujarat, India
Aura Lifecare Private Limited U24230GJ2012PTC070929 Savli, Gujarat, India
Sriven Pharmachem India Private Limited U24233TG2015PTC097894 Tirumalagiri, Telangana, India
Par Drugs L24117GJ1999PLC035512 Vadodara, Gujarat, India
Biosystems U29297TN2003PTC051492 Sriperumbdur, Tamil Nadu, India
Shlokka Dyes Limited U24299GJ2021PLC124004 Vagra, Gujarat, India
Parpharm U24232TN2013PTC093471 Chennai, Tamil Nadu, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Satyadeva Pharmaceuticals Private Limited before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Satyadeva Pharmaceuticals Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 90/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 55/100, margin trends, ownership structure and peer set for Satyadeva Pharmaceuticals Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 92/100, distress signals and MSME payment-delay disclosures - know whether Satyadeva Pharmaceuticals Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Satyadeva Pharmaceuticals Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Satyadeva Pharmaceuticals Private Limited an active company?

Satyadeva Pharmaceuticals Private Limited has MCA status “Active” with a compliance score of 100/100 (Low Risk).

Is Satyadeva Pharmaceuticals Private Limited financially healthy?

Satyadeva Pharmaceuticals Private Limited has a Financial Health Score of 85/100 (Low Risk) based on its filed financial statements.

Should I do business with Satyadeva Pharmaceuticals Private Limited?

Its overall Trust Score is 92/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Satyadeva Pharmaceuticals Private Limited?

See the directors and ownership sections above for board and shareholding detail. 5 active director(s) are on record.

Does Satyadeva Pharmaceuticals Private Limited have loans or charges against its assets?

3 open charge(s) are registered against its assets, and 5 earlier charge(s) stand satisfied.

Is Satyadeva Pharmaceuticals Private Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).

Is it risky to lend to Satyadeva Pharmaceuticals Private Limited?

Its Credit Risk Score is 90/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.